Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 May 27;13(5):e15275.
doi: 10.7759/cureus.15275.

A Patient With Regressed Diffuse Large B-Cell Lymphoma and Aggressive Follicular Lymphoma

Ashish K Sethi  1 , Bushra Haq  1
Affiliations
Case Reports

A Patient With Regressed Diffuse Large B-Cell Lymphoma and Aggressive Follicular Lymphoma

Ashish K Sethi et al. Cureus. .

Abstract

Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) are the two most aggressive forms of non-Hodgkin lymphomas (NHLs). Spontaneous remission of DLBCL is a rare phenomenon. Immune system activation has been observed to play a significant role in the regression of untreated disease on some occasions. We present a case of DLBCL in a 75-year-old male patient who has been free of disease for two months without any treatment due to possible immune-related mechanism, but later he presented with FL.

Keywords: diffuse large b-cell lymphoma; follicular lymphoma; hiv lymphoma; non-hodgkin lymphoma; r-chop therapy; spontaneous regression.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PET scan showing right hilar mass (green arrow)
Figure 2
Figure 2. PET scan showing right axillary mass (green arrow)
Figure 3
Figure 3. CT scan showing axillary mass/lymphadenopathy (red arrow)
Figure 4
Figure 4. CT scan showing right hilar mass
Figure 5
Figure 5. CT scan showing splenomegaly
Figure 6
Figure 6. Axillary lymph node biopsy
Large lymphocytes (red arrow), nuclear pleomorphism, and prominent nucleoli (yellow arrow) can be seen.
Figure 7
Figure 7. PET scan showing no axillary mass
Figure 8
Figure 8. PET scan showing no SUV/FDG uptake in the hilar region
SUV, standardized uptake value; FDG, fluorodeoxyglucose
Figure 9
Figure 9. PET scan showing submental lymhadenopathy
FDG uptake is seen in the right submental lymph node FDG, fluorodeoxyglucose
Figure 10
Figure 10. Submental biopsy showing follicular lymphoma (CD21 positive)
Figure 11
Figure 11. Submental lymph node biopsy showing follicular lymphoma (CD21 positive with dendritic meshwork pattern)
See this image and copyright information in PMC

References

    1. Diffuse large B-cell lymphoma. Sehn LH, Salles G. N Engl J Med. 2021;384:842–858. - PMC - PubMed
    1. Primary extra-nodal diffuse large B-cell lymphoma: a prognostic analysis of 141 patients. Shen H, Wei Z, Zhou D, et al. Oncol Lett. 2018;16:1602–1614. - PMC - PubMed
    1. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Castillo JJ, Winer ES, Olszewski AJ. Am J Hematol. 2014;89:310–314. - PubMed
    1. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Zhou Z, Sehn LH, Rademaker AW, et al. Blood. 2014;123:837–842. - PMC - PubMed
    1. Spontaneous remission and concomitant progression in a patient with DLBCL. Han EJ, Kim J, Park SY, O JH. Diagnostics (Basel) 2020;10:950. - PMC - PubMed

Publication types

LinkOut - more resources